Cargill Bioengineering LLC

Belkins
Cargill Bioengineering LLC is a consulting company specializing in providing Biomedical and Biomechanical Consulting services. Cargill Bioengineering is led by Dr. Bob Cargill, a consultant with over 10 years of consulting experience and 5 years on the academic faculty of Georgia Tech. Cargill Bioengineering is responsive, effective, and efficient with experience spanning mutliple and diverse fields.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

Genetic Literacy Project | January 14, 2020

news image

Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE....

Read More

CELL AND GENE THERAPY

SHORELINE BIOSCIENCES ANNOUNCES $140M FINANCING TO ADVANCE PIPELINE OF NEXT GENERATION CELL IMMUNOTHERAPIES

Shoreline Biosciences | November 02, 2021

news image

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Supers...

Read More

TYLIGAND BIOSCIENCE AND CONTEXT THERAPEUTICS SIGN STRATEGIC DEVELOPMENT AGREEMENT FOR ONAPRISTONE ER

BioSpace | March 12, 2020

news image

Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, and Context Therapeutics LLC, a clinical stage biopharmaceutical company focused on hormone driven cancers, today announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). Onapristone ER is currently being evaluated in patients with progesterone receptor positive (PR+) ovarian and endometrial cancers in t...

Read More

CELL AND GENE THERAPY

MUSC AND HELIX LAUNCH IN OUR DNA SC, FIRST-OF-ITS-KIND POPULATION GENOMICS PROGRAM TO DRIVE PREVENTIVE, PRECISION HEALTH CARE FOR SOUTH CAROLINIANS

Helix | September 21, 2021

news image

The Medical University of South Carolina (MUSC) and Helix have announced a strategic collaboration to develop a first-of-its-kind population genomics initiative in South Carolina called In Our DNA SC. The large-scale program is designed to improve health care outcomes by integrating genetic insights into clinical care and research. The statewide initiative will enroll 100,000 patients in genetic testing over the next four years at no cost to the patient. The program will enable th...

Read More
news image

GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

Genetic Literacy Project | January 14, 2020

Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE....

Read More
news image

CELL AND GENE THERAPY

SHORELINE BIOSCIENCES ANNOUNCES $140M FINANCING TO ADVANCE PIPELINE OF NEXT GENERATION CELL IMMUNOTHERAPIES

Shoreline Biosciences | November 02, 2021

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Supers...

Read More
news image

TYLIGAND BIOSCIENCE AND CONTEXT THERAPEUTICS SIGN STRATEGIC DEVELOPMENT AGREEMENT FOR ONAPRISTONE ER

BioSpace | March 12, 2020

Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, and Context Therapeutics LLC, a clinical stage biopharmaceutical company focused on hormone driven cancers, today announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). Onapristone ER is currently being evaluated in patients with progesterone receptor positive (PR+) ovarian and endometrial cancers in t...

Read More
news image

CELL AND GENE THERAPY

MUSC AND HELIX LAUNCH IN OUR DNA SC, FIRST-OF-ITS-KIND POPULATION GENOMICS PROGRAM TO DRIVE PREVENTIVE, PRECISION HEALTH CARE FOR SOUTH CAROLINIANS

Helix | September 21, 2021

The Medical University of South Carolina (MUSC) and Helix have announced a strategic collaboration to develop a first-of-its-kind population genomics initiative in South Carolina called In Our DNA SC. The large-scale program is designed to improve health care outcomes by integrating genetic insights into clinical care and research. The statewide initiative will enroll 100,000 patients in genetic testing over the next four years at no cost to the patient. The program will enable th...

Read More